Literature DB >> 23982853

SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013.

R Mesía1, M Pastor, J J Grau, E del Barco.   

Abstract

Head and neck cancer represents 5 % of oncologic cases in adults. Early stage treatments are local with surgery and/or radiotherapy. For locally advanced stages, treatment requires radiotherapy combined with platinum-based drugs or cetuximab. Induction chemotherapy should be considered for selected cases. In the case of metastatic disease, adjuvant or palliative treatment is based on platinum agents and cetuximab.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23982853     DOI： 10.1007/s12094-013-1096-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  17 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

Review 2.  Head and neck cancer.

Authors:  A Forastiere; W Koch; A Trotti; D Sidransky
Journal:  N Engl J Med       Date:  2001-12-27       Impact factor: 91.245

Review 3.  Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis.

Authors:  Eric Winquist; Tom Oliver; Ralph Gilbert
Journal:  Head Neck       Date:  2007-01       Impact factor: 3.147

4.  Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Authors:  R Hitt; A Irigoyen; H Cortes-Funes; J J Grau; J A García-Sáenz; J J Cruz-Hernandez
Journal:  Ann Oncol       Date:  2011-08-23       Impact factor: 32.976

5.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

6.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

7.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Authors:  Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

8.  Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.

Authors:  Yoann Pointreau; Pascal Garaud; Sophie Chapet; Christian Sire; Claude Tuchais; Jacques Tortochaux; Sandrine Faivre; Stephane Guerrif; Marc Alfonsi; Gilles Calais
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

9.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

10.  Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.

Authors:  Jean-Louis Lefebvre; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-01       Impact factor: 7.038
View more
  4 in total

1.  SEOM guidelines 2013: a response to the needs of Spanish oncologists.

Authors:  J J Cruz-Hernández; C A Rodríguez
Journal:  Clin Transl Oncol       Date:  2013-08-08       Impact factor: 3.405

2.  Evaluation of nutritional status in head and neck radio-treated patients affected by oral mucositis: efficacy of class IV laser therapy.

Authors:  M Gobbo; G Ottaviani; G Perinetti; F Ciriello; A Beorchia; M Giacca; R Di Lenarda; K Rupel; G Tirelli; S Zacchigna; M Biasotto
Journal:  Support Care Cancer       Date:  2014-02-20       Impact factor: 3.603

Review 3.  Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.

Authors:  Alex Françoso; Patricia Ucelli Simioni
Journal:  Drug Des Devel Ther       Date:  2017-01-11       Impact factor: 4.162

4.  Diagnostic and therapeutic features associated with modification of quality-of-life's outcomes between one and six months after major surgery for head and neck cancer.

Authors:  Margherita Gobbo; Federica Bullo; Giuseppe Perinetti; Annalisa Gatto; Giulia Ottaviani; Matteo Biasotto; Giancarlo Tirelli
Journal:  Braz J Otorhinolaryngol       Date:  2015-12-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.